Minhai Biotechnology was invited to attend the inaugural China Pharmaceutical Valley Future Biologics Innovative Drug Conference.

Release date:

2024-11-18

Author:

Source:


Abstract

On November 16, the inaugural China Pharmaceutical Valley Future Biologics Innovative Drug Conference was successfully held at the Kapok Hotel in Daxing District. Hosted by the Management Committee of the Daxing Biopharmaceutical Industry Base of Zhongguancun Science Park and co-organized by six entities—including Beijing Hotgen Biotechnology Co., Ltd. and Beijing Minhai Biotechnology Co., Ltd.—the event brought together numerous academicians, industry experts, and leading entrepreneurs to discuss cutting-edge industry trends, foster deep integration of key factors driving the pharmaceutical and healthcare sectors, and further enhance Daxing District’s influence in the field of innovative drugs. Zheng Haifa, Chief Scientist of Kintor Pharmaceutical and General Manager of Minhai Biotechnology, was invited to attend the conference.

11 16th of the month On [date], the inaugural China Pharmaceutical Valley – Future Biologics Innovative Drug Conference was successfully held at the Kapok Hotel in Daxing District. Hosted by the Management Committee of the Daxing Biopharmaceutical Industry Base of Zhongguancun Science Park and co-organized by six entities, including Beijing Hotgen Biotechnology Co., Ltd. and Beijing Minhai Biotechnology Co., Ltd., the event brought together numerous academicians, industry experts, and leading entrepreneurs to discuss cutting-edge industry trends, foster the deep integration of key drivers for the pharmaceutical and healthcare sectors, and further enhance Daxing District’s influence in the field of innovative drugs.

Zheng Haifa, Chief Scientist of Kangtai Biological and General Manager of Minhai Biological, was invited to attend the conference, where he delivered a live presentation titled “Trends in the Development of Next-Generation Vaccines,” and Together with other corporate representatives The unveiling ceremony marking the establishment of the “China Pharmaceutical Valley Biopharmaceutical Industry Alliance” was held.

In his on-site presentation, General Manager Zheng provided a clear and accessible overview of the background knowledge surrounding vaccines, offered a detailed analysis of emerging vaccine technology platforms, and outlined key trends and directions in the future development of vaccine technologies—such as multivalent and combination vaccines, viral vector vaccines, and novel adjuvants—eliciting an enthusiastic response from the audience.

At the event, President Zheng stated that China’s biopharmaceutical industry today faces both opportunities and challenges, and called on all sectors to provide greater support for the innovative development of biopharmaceutical companies. He expressed hope that, taking the convening of this conference and the establishment of the “China Pharmaceutical Valley Biopharmaceutical Industry Alliance” as a catalyst, more high‑quality enterprises would be brought together to jointly elevate China’s pharmaceutical R&D capabilities and help more outstanding domestically developed innovative drugs gain international recognition.

Looking ahead, Minhai Biologics will continue to serve as a leader in technological innovation within the biopharmaceutical industry. Leveraging the Daxing District Biopharmaceutical Industry Base and the high‑quality platform of the China Pharmaceutical Valley Biopharmaceutical Industry Alliance, the company will further strengthen cluster‑effect advantages and make even greater contributions to advancing the overall high‑quality development of China’s pharmaceutical and healthcare sectors.

 

 

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09